Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II (Single Center, Open, Phase I and Multicenter, Double-Blinded, Randomized, Placebo-Controlled, Phase II) Trial to Evaluate the Safety and Immunogenicity of the AdCLD-CoV19-1 OMI Administered as a Booster to Healthy Adults Aged 19 Years Old and Above

NCT05576623 is registered in ClinicalTrials.gov with Cellid Co., Ltd. as lead sponsor.

NCT NCT05576623
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05576623 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II (Single Center, Open, Phase I and Multicenter, Double-Blinded, Randomized, Placebo-Controlled, Phase II) Trial to Evaluate the Safety and Immunogenicity of the AdCLD-CoV19-1 OMI Administered as a Booster to Healthy Adults Aged 19 Years Old and Above
Lead sponsor
Cellid Co., Ltd.
Phase
Phase 1/2
Overall status
Completed
Start date
September 14, 2022
Completion date
February 28, 2024
Enrollment
320 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, vaccines